Should Investors Adopt Trump’s Pro-Russian Stance?
Should investors take a cue from President Trump and adopt a favorable position towards Russia – whose stock market and currency showed strong performance last…
Trading On Trump’s Tweets: There’s An App For That!
“Our mission is to build the next generation mobile investing platform that uses natural language, a wealth of data and artificial intelligence to help investors…
2 “Bulletproof” Defense Stocks To Consider On Lifting Of Spending Caps
Defense spending has been constrained over the last five years due to caps imposed by the Budget Control Act of 2011. However, like a lot…
The Industry “Nobody Is Talking About” That Could See A Profit Boom From The Driverless Car Movement
Of the trend towards driverless cars, today’s article notes that “the movement now appears unstoppable.” But, with all the attention directed at the companies behind…
Investing In The Era Of Trump: Go With POTUS Indexes?
“Direct your attention to the relentless tweeting of the man who soon will be president. There is valuable information in those 140 characters that can…
20 High Yield Dividend Stocks Set For Sales And Earnings Gains
While acknowledging that last year’s “flight to yield” resulted in some dividend stocks appearing risky with their relatively high valuations, the author of today’s article…
Bullish On The Big Banks: Why 2017 May Be The Most Profitable Year In Wall Street’s History
With the prospect of higher interest rates, stronger growth and less regulation, stocks of Wall Street banks have soared since Election Day, with firms such…
3 Overlooked Stocks Worth Looking Over
After examining the trends in stocks, bonds and gold, the author of today’s article concludes that “the real opportunities in 2017 appear to be in…
Will The Worst Become First? 5 Terrible Investments Of 2016 To Consider For 2017
Will the worst of 2016 be among the first of 2017? The author of today’s article highlights five poor performers from 2016 that he believes…
The 21st Century Cures Act: How Investors Can Profit From This Potential “Boon For Big Pharma”
Today’s article notes that it takes almost $1 billion to bring a new drug to market, stifling competition and allowing drug companies to charge Americans…